Clinical Cancer Research CR Helping Patients Advances in Breast Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Clinical Cancer Research 13, 2831, May 15, 2007. doi: 10.1158/1078-0432.CCR-06-2522
© 2007 American Association for Cancer Research
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ross, J. S.
Right arrow Articles by Hortobagyi, G. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ross, J. S.
Right arrow Articles by Hortobagyi, G. N.

Perspective

Standardizing Slide-Based Assays in Breast Cancer: Hormone Receptors, HER2, and Sentinel Lymph Nodes

Jeffrey S. Ross1, W. Fraser Symmans2, Lajos Pusztai3 and Gabriel N. Hortobagyi3

Authors' Affiliations: 1 Department of Pathology and Laboratory Medicine, Albany Medical College, Albany, New York, and Divisions of 2 Pathology and 3 Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

Requests for reprints: Jeffrey S. Ross, Department of Pathology and Laboratory Medicine, Albany Medical College, 47 New Scotland Avenue, Albany, NY 12208. Phone: 518-262-5461; Fax: 518-262-8092; E-mail: rossj{at}mail.amc.edu.


   Abstract
Top
 Abstract
Background
 Hormone Receptor Assays
 HER2 testing
 References
 
Despite the rapid expansion of novel diagnostics designed to personalize breast cancer care, there remain several significant unmet needs for improving the accuracy and reliability of tests that are already in common daily clinical practice. For example, although immunohistochemistry has been the predominant method for measuring estrogen receptor and progesterone receptor status for over 15 years, this assay remains unstandardized and there is a widespread concern that inaccuracy in immunohistochemistry technique and interpretation is leading to an unacceptably high error rate in determining the true hormone receptor status. Similarly, there is considerable concern that both false-negative and false-positive result rates for testing for HER2 status are unacceptably high in current clinical practice. This commentary considers a variety of factors, including preanalytic conditions and slide-scoring procedures, and other variables that may be contributing to current testing error rates and why there is a great need for the standardization of these biomarker assay procedures to further enable the highest possible quality of care for newly diagnosed breast cancer patients.


   Background
Top
 Abstract
 Background
Hormone Receptor Assays
 HER2 testing
 References
 
In 1998, the simultaneous regulatory approvals of trastuzumab (Herceptin) and the HercepTest immunohistochemistry diagnostic for patients with HER2-overexpressing metastatic breast cancers launched the era of drug and test combinations (1, 2). The recent clinical trial results and U.S. Food and Drug Administration approval of trastuzumab-based therapy in the adjuvant setting (3, 4), the development of the dual kinase inhibitor, lapatinib (5), and the evolution of the antiangiogenesis antibody, bevacizumab (6), have maintained this enthusiasm for targeted therapies. Despite the rapid expansion of novel diagnostics designed to personalize breast cancer care, however, there remain several significant unmet needs for improving the accuracy and reliability of tests that are already in common daily clinical practice. In addition, the preanalytic conditions known to influence the final interpretation of these tests are in serious need of standardization (7–9). Thus, as we look forward to the introduction of new individualized breast cancer therapies, we must also look back and repair the defects in the personalized medicine tests that are already heavily relied on for the selection of therapy for the disease.


   Hormone Receptor Assays
Top
 Abstract
 Background
 Hormone Receptor Assays
HER2 testing
 References
 
Measurement of estrogen and progesterone receptor (ER/PR) status (Table 1 ) is a standard of practice for newly diagnosed breast cancer patients and used to guide the selection of patients to receive hormonal therapies (10, 11). Although immunohistochemistry has been the predominant method for measuring ER/PR for over 15 years, this assay remains unstandardized and there is widespread concern that inaccuracy in immunohistochemistry technique and interpretation is leading to an unacceptably high error rate in determining the true hormone receptor status (10–13). Moreover, the emergence of additional hormonal-based therapeutics beyond tamoxifen, including aromatase inhibitors, selective estrogen response modulators, and selective ER down-regulators, and the possibility that these drugs may be more efficacious for patients with lower ER/PR expression levels have further intensified interest in improving the accuracy of immunohistochemistry and/or the consideration of alternative diagnostic methods (14). About 60% of ER+ tumors are also PR+ and ~75% of these ER+/PR+ tumors respond positively to endocrine therapy (15). It has been suggested that PR may be necessary for responsiveness to hormonal therapy in that ER+/PR– tumors are generally less responsive than ER+/PR+ tumors, possibly indicating that the estrogen response pathway may be deactivated in the ER+/PR– cases. ER–/PR+ tumors are rare and seem to show an intermediate response to endocrine therapy (15). Although practicing oncologists rely on the negative predictive value of the ER/PR assays, the relatively low positive predictive value of the tests (range, 30-50%) continues to contribute to the failure to achieve ideal personalized management of patients with breast cancer. Although the Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer (St. Gallen, Switzerland) concluded that a precise threshold for ER/PR immunohistochemistry scoring results was difficult to achieve, a 10% positive staining of cells for either receptor might be considered as a reasonable threshold that could be accepted by most (16). Thus, either significant improvements and further standardization must be made in immunohistochemistry testing or novel, more reliable approaches to ER/PR testing must be introduced.


View this table:
[in this window]
[in a new window]

  		Table 1. Assays for measuring ER/PR status

 
Preanalytic issues. Some of the most significant issues that affect the performance of tissue-based biomarker assays in breast cancer are the events that take place before the performance of the actual test (8, 9, 15–19). These preanalytic issues include the duration and conditions under which the tissue is maintained before fixation; the nature (chemical composition) and duration of fixation; the tissue processing conditions (standard versus the new non-formalin–based rapid processing techniques); the temperature of the embedding material; the length of storage of unstained slides before assessment by immunohistochemistry, fluorescent, nonfluorescent chromogenic, and silver in situ hybridization procedures (respectively; FISH, CISH, and SISH); and the use and nature of antigen-retrieval procedures, including both heat- and enzyme-based methods. These preanalytic variables significantly affect ER/PR results (15–19), which is highlighted by the increase in hormone receptor immunostaining as a function of length of formalin fixation (20). In one study, 200 clinical laboratories received sections from the same three tumors that showed low, moderate, or high ER expression, respectively, in a reference laboratory. Each laboratory did its own immunohistochemistry assessment and the results indicated considerable interlaboratory variation (21). The false-negative rates were as high as 30% to 60% (depending on the cutoff) in the low ER+ case.

Can ER/PR immunohistochemistry assays be improved? When immunohistochemistry was first introduced into clinical practice in the early 1990s, it was hoped that it would do in a manner equal or superior to the biochemical competitive binding assay that it replaced. After more than 15 years of experience, however, it is clear that response rates to targeted hormonal therapies have not dramatically increased in the immunohistochemistry testing era, and mRNA transcriptional profiling studies suggest that in ~10% of immunohistochemistry-determined ER+ tumors, active downstream signaling of the ER gene pathway is not observed. These facts have led to several recommendations as to how immunohistochemistry-based ER/PR testing performance can be improved: (a) test kits should be standardized to include cell line or tissue controls of known ER and PR protein expression levels determined by Western blotting; (b) the antibodies used to detect ER protein should be improved to avoid false-positive staining for tumors with ER gene mutations; (c) the automated or manual staining procedures, the preanalytic conditions (fixative, length of fixation, block or unstained slide storage time, and conditions), and the staining protocols (type and intensity of antigen retrieval, antibody concentration, and type of signal detection chemistry) should be standardized; (d) a universal immunohistochemistry slide scoring method should be used (22); (e) if a manual scoring method is used, an agreed upon cutoff for ER positivity should be established, whether this is a single variable or a more elaborate system, such as the method developed by Rhodes et al. (23); (f) if an image analysis system is used to score slides, the microscope, imaging instrument, and the software must be standardized and validated against another method of ER/PR measurement (23); and (g) widespread use of peer-reviewed quality assurance programs should be adopted by all laboratories providing ER/PR test results (24, 25).

Will immunohistochemistry get the message? When current immunohistochemistry procedures are used for ER/PR on well-maintained tissues, a linear relationship between the intensity and distribution of the immunostaining and the amount of nuclear ER protein is not observed (26). There is a concern, therefore, as to whether current immunohistochemistry techniques are capable of developing a sufficient dynamic range to allow for further personalization of hormone receptor–targeted therapies by guiding the actual drug selection in known ER+ patients. Thus, the 2001 U.S. NIH Consensus Conference conclusion that any level of immunohistochemistry-based expression of ER protein was sufficient to classify a tumor as ER+ may now need to be reconsidered (27). Breast cancer hormone receptor mRNA levels feature a wider dynamic range than current immunohistochemistry protocols, can be measured by both the reverse transcription-PCR and genomic microarray methods (26), and have been used both to classify and predict prognosis for the disease (28, 39). Genomic microarrays and multiplex reverse transcription-PCR assays also have the ability to assess ER pathway activation by the simultaneous determination of expression of multiple relevant genes and downstream pathways (30). Of recent interest is the question as to whether low and intermediate ER mRNA levels in ER immunohistochemistry-positive tumors predict responsiveness to aromatase inhibitors, but not to tamoxifen. Only prospective studies using large cohorts of patients in various clinical settings can satisfactorily answer this question. In addition, reverse transcription-PCR and microarray-based tests for ER must also be standardized with reproducible controls and established relative mRNA expression cutoff points before they can be considered for widespread clinical use. Finally, additional potential biomarkers of hormone receptor function, including PR status and others, such as BCL-2 expression, must also be evaluated for their ability to customize hormone receptor–targeted therapy for both newly diagnosed and recurrent tumors (31). Therefore, whether by improvement and standardization of immunohistochemistry, transition to mRNA-based testing, or the introduction of additional validated biomarkers, it is now widely anticipated that hormone receptor testing in breast cancer must and will be enhanced to further personalize breast cancer care in an emerging era of increasing hormonal targeted therapy choices.


   HER2 testing
Top
 Abstract
 Background
 Hormone Receptor Assays
 HER2 testing
References
 
Will CISH or SISH replace FISH and immunohistochemistry? Today, as anti-HER2–targeted therapy expands to the adjuvant setting, the importance of HER2 testing accuracy has never been more important. Worldwide, immunohistochemistry is the most often used primary test, with FISH testing continuing to grow incrementally (Fig. 1 ; Table 2 ; ref. 2). The transition to primary FISH testing has been triggered, in part, by concerns over the accuracy of immunohistochemistry results, especially when originating from small volume laboratories (32, 33), and a retrospective study that showed superiority of FISH-based testing over immunohistochemistry for the prediction of trastuzumab response (34). Recently, a task force report from the National Comprehensive Cancer Network concluded that properly done immunohistochemistry testing was as accurate as FISH in predicting trastuzumab response (35). The relative strengths and weaknesses of immunohistochemistry and FISH have been widely discussed in the literature (2). The advantages of immunohistochemistry, such as advantages of low cost, ease of performance, and widespread familiarity, must be weighed against a potential 10% false-negative rate that might prevent thousands of newly diagnosed women from being considered candidates for treatment with a drug that has shown substantial efficacy in the treatment of their disease, both in early and late stages (1, 3, 4). One strategy that can conceivably reduce the false-negative rate for immunohistochemistry is to make certain that a known 3+ positive cell line or tissue section is placed on the same slide as the patient's tumor to prevent a technique error (e.g., failure to apply reagents) from causing a false-negative result. Similarly, stringent adherence to published slide scoring criteria and avoiding overscoring of cases with thermal artifacts, edge staining only, and especially, improper scoring of cases with staining of benign breast epithelium can similarly reduce the false (3+)-positive scoring rate. For FISH-based testing, despite the advantages of a more stable DNA target and the built-in internal control HER2 (ERBB2) gene signals in adjacent benign epithelium (or unamplified tumors), the use of the technique has been limited by its significantly higher cost in equipment, reagents, and personnel and the general lack of familiarity with the technique in smaller laboratories and community hospitals. Although discordance among laboratories in FISH testing has been lower than immunohistochemistry in some studies (32), this has not been the case for others (33). In addition, some investigators have recommended simultaneous measurement of HER2 gene amplification and protein overexpression (36). Thus, as described previously for ER/PR testing, the most important approach to achieving improved accuracy for both immunohistochemistry and FISH-based assays is for all laboratories that provide this type of testing to participate in peer reviewed quality assurance programs that include proficiency testing (33).


Figure 1
View larger version (50K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 1. HER2 testing. A, 3+ membrane staining by immunohistochemistry using the DAKO HercepTest. B, gene amplification detected by FISH with ratio of HER2 signals to chromosome 17 centromere signals of 5.7 using the Abbott-Vysis Pathvysion System. C, HER2 gene amplification detected by CISH using the Invitrogen-Zymed system.

 

View this table:
[in this window]
[in a new window]

  		Table 2. Assays for determining HER2 status

 
Additional approaches to HER2 gene amplification testing that potentially feature the low cost and convenience of immunohistochemistry and the higher accuracy and built-in internal control advantages of FISH are the CISH (Invitrogen, Inc.) and the SISH (Ventana Medical Systems, Inc.) techniques. These methods use a complementary probe to the HER2 gene sequence similar to the FISH assay, but use immunohistochemistry-type signal detection in place of fluorescence and can be scored with a conventional light microscope while preserving the background tumor histology. Despite these potential advantages, the CISH (37) and SISH (38) techniques have several potential drawbacks, including hybridization failures, difficulty in counting overlapping gene signals, and classifying cases whose average gene copy number is close to the threshold of a positive result. A commercial version of the CISH assay is currently under review by the U.S. Food and Drug Administration seeking a similar indication for selection of patients for eligibility to receive trastuzumab as exists for previous Food and Drug Administration–approved immunohistochemistry and FISH assays. CISH has shown high concordance with FISH (37) and has the potential to replace both the immunohistochemistry and FISH techniques for primary HER2 testing in that it would have the total cost, convenience, and familiarity advantages associated with immunohistochemistry and eliminate the need for a triage system that requires 2+ immunohistochemistry results to be retested by FISH. Undoubtedly, there will be great interest among oncologists and pathologists to see if the HER2 testing landscape actually does change in this way over the next several years.

Sentinel Lymph Nodes. Over the last 10 years, the sentinel lymph node (SLN) procedure has become a routine approach to the management of newly diagnosed breast cancers (39). There is significant lack of standardization, however, as to how the removed lymph nodes will be assessed by pathology departments (40). Variations in procedures include the following: (a) whether intraoperative frozen sections are used; (b) whether touch preparations with cytologic interpretations are incorporated; (c) the extent of serial sectioning of subsequent permanent paraffin blocks; and (d) the use and conditions associated with ancillary immunohistochemistry procedures (Fig. 2 ). In addition, nonmorphologic molecular methods for detecting metastases and microdeposits in SLNs have been developed and are undergoing clinical trials (41). Thus, given the multiple methods of tissue assessment available, it is no surprise that the SLN evaluation is far from standardized. A major concern is the use of the 0.2- and 2.0-mm cutoffs for determining the final pathologic stage, which were originally determined by a retrospective analysis of lymph node metastasis size and long-term disease outcome (42). Currently, SLNs with isolated tumor cells, small aggregates, or tumor cell clusters measuring <0.2 mm are given the designation N0I+ to indicate that the microdeposits identified only by immunohistochemistry were <0.2 mm in greatest diameter. There is concern whether these patients can safely be considered SLN negative and whether a better assessment than on slide diameter measurements could be developed for these cases. In ~18% of SLN biopsies, immunohistochemistry will detect occult tumor cells and clusters not identified on routine microscopy (43). Although it is widely accepted that the N0I+ status, also known as nanometastasis, imparts a significantly poorer prognosis than for N0 patients (44), confirmatory data from large prospective studies are lacking. Consequently, both the International Society of Cell Therapy and the National Cancer Institute have recognized the need for standardization of the SLN immunohistochemistry assay. Thus, the clinical management of patients with N0I+ disease remains controversial (45, 46). One emerging approach to this dilemma is the breast cancer stem cell concept that holds that the spread of stem cells to the SLN and bone marrow sinuses indicates a high risk for subsequent relapse and metastatic disease development after the completion of primary treatment (47, 48). Thus, if the phenotypic markers of breast cancer stem cells could be determined and applied to the <0.2-mm microdeposits in SLNs, this might lead to a more rational and biologically sound approach to the pathologic staging procedure. As further information on breast cancer stem cells emerges, it will be of great interest how these findings can be applied to this continuing clinical problem.


Figure 2
View larger version (80K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 2. Microdeposits in a SLN detected only by immunohistochemistry. These deposits are well below the 0.2-mm cutoff and this patient was staged as "N0I+".

 

   Footnotes
 
Note: The manuscript has been approved by the Albany Medical Center Institutional Review Board for submission for publication.

Received 10/17/06; revised 12/26/06; accepted 1/ 9/07.


   References
Top
 Abstract
 Background
 Hormone Receptor Assays
 HER2 testing
 References
 

  1. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783–92.[Abstract/Free Full Text]
  2. Ross JS, Fletcher JA, Linette GP, et al. The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 2003;8:307–25.[Abstract/Free Full Text]
  3. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673–84.[Abstract/Free Full Text]
  4. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659–72.[Abstract/Free Full Text]
  5. Konecny GE, Pegram MD, Venkatesan N, et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 2006;66:1630–9.[Abstract/Free Full Text]
  6. Sledge GW, Jr. VEGF—targeting therapy for breast cancer. J Mammary Gland Biol Neoplasia 2005;10:319–23.[CrossRef][Medline]
  7. Robison JE, Perreard L, Bernard PS. State of the science: molecular classifications of breast cancer for clinical diagnostics. Clin Biochem 2004;37:572–8.[CrossRef][Medline]
  8. Schnitt SJ. Traditional and newer pathologic factors. J Natl Cancer Inst Monogr 2001;30:22–6.[Abstract/Free Full Text]
  9. Masood S. Standardization of immunobioassays as surrogate endpoints. J Cell Biochem Suppl 1994;19:28–35.[Medline]
  10. Osborne CK. Steroid hormone receptors in breast cancer management. Breast Cancer Res Treat 1998;51:227–38.[CrossRef][Medline]
  11. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999;17:1474–81.[Abstract/Free Full Text]
  12. Geurts-Moespot J, Leake R, Benraad TJ, Sweep CG; On behalf of the EROTC Receptor and Biomarker Study Group. Twenty years of experience with the steroid receptor external quality assessment program—the paradigm for tumour biomarker EQA studies. Int J Oncol 2000;17:13–22.[Medline]
  13. Kurosumi M. Significance of immunohistochemical assessment of steroid hormone receptor status for breast cancer patients. Breast Cancer 2003;10:97–1.[Medline]
  14. Buzdar AU, Robertson JF, Eiermann W, Nabholtz JM. An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane. Cancer 2002;95:2006–16.[CrossRef][Medline]
  15. Elledge RM, Fuqua SA. Estrogen and progesterone receptors. In: Harris JR, editor. Diseases of the breast. Vol. 2. Philadelphia: Lippincott Williams & Wilkins; 2000. p. 471–88.
  16. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Senn HJ; Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. Meeting highlights: international consensus panel on the treatment of primary breast cancer. J Clin Oncol 2001;19:3817–27.[Free Full Text]
  17. Diaz LK, Sneige N. Estrogen receptor analysis for breast cancer: current issues and keys to increasing testing accuracy. Adv Anat Pathol 2005;12:10–9.[CrossRef][Medline]
  18. Ross JS. Improving the accuracy of hormone receptor assays in breast cancer: an unmet medical need. Future Oncol 2005;1:439–41.[CrossRef][Medline]
  19. Schnitt SJ. Estrogen receptor testing of breast cancer in current clinical practice: what's the question? J Clin Oncol 2006;24:1797–9.[Free Full Text]
  20. Goldstein NS, Ferkowicz M, Odish E, Mani A, Hastah F. Minimum formalin fixation time for consistent estrogen receptor immunohistochemical staining of invasive breast carcinoma. Am J Clin Pathol 2003;120:86–92.[CrossRef][Medline]
  21. Rhodes A, Jasani B, Barnes DM, Bobrow LG, Miller KD. Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems. J Clin Pathol 2000;53:125–30.[Abstract/Free Full Text]
  22. Herynk MH, Fuqua SA. Estrogen receptor mutations in human disease. Endocr Rev 2004;25:869–98.[Abstract/Free Full Text]
  23. McCabe A, Dolled-Filhart M, Camp RL, Rimm DL. Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis. J Natl Cancer Inst 2005;97:1808–15.[Abstract/Free Full Text]
  24. Rüdiger T, Höfler H, Kreipe H, et al. Quality assurance in immunohistochemistry: results of an interlaboratory trial involving 172 pathologists. Am J Surg Pathol 2002;26:873–82.[CrossRef][Medline]
  25. Rhodes A. Quality assurance in immunohistochemistry. Am J Surg Pathol 2003;27:1284–5.[Medline]
  26. Hayashi S. Prediction of hormone sensitivity by DNA microarray. Biomed Pharmacother 2004;58:1–9.[CrossRef][Medline]
  27. Eifel P, Axelson JA, Costa J, et al. NIH Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1–3, 2000. J Natl Cancer Inst 2001;93:979–89.[Abstract/Free Full Text]
  28. Pusztai L, Ayers M, Stec J, et al. Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors. Clin Cancer Res 2003;9:2406–15.[Abstract/Free Full Text]
  29. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;406:747–52.[CrossRef][Medline]
  30. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817–26.[Abstract/Free Full Text]
  31. Tovey S, Dunne B, Witton CJ, Forsyth A, Cooke TG, Bartlett JM. Can molecular markers predict when to implement treatment with aromatase inhibitors in invasive breast cancer? Clin Cancer Res 2005;11:4835–42.[Abstract/Free Full Text]
  32. Tubbs RR, Pettay JD, Roche PC, Stoler MH, Jenkins RB, Grogan TM. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J Clin Oncol 2001;19:2714–21.[Abstract/Free Full Text]
  33. Roche PC, Suman VJ, Jenkins RB, et al. Concordance between local and central laboratory HER2 testing in the Breast Intergroup Trial N9831. J Natl Cancer Inst 2002;94:855–7.[Abstract/Free Full Text]
  34. Dybdal N, Leiberman G, Anderson S, et al. Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab. Breast Cancer Res Treat 2005;93:3–11.[Medline]
  35. Carlson RW, Moench SJ, Hammond ME, et al. HER2 testing in breast cancer: NCCN Task Force report and recommendations. J Natl Compr Canc Netw 2006;4 Suppl 3:S1–22.
  36. Lottner C, Schwarz S, Diermeier S, et al. Simultaneous detection of HER2/neu gene amplification and protein overexpression in paraffin-embedded breast cancer. J Pathol 2005;205:577–84.[CrossRef][Medline]
  37. Hanna WM, Kwok K. Chromogenic in-situ hybridization: a viable alternative to fluorescence in-situ hybridization in the HER2 testing algorithm. Mod Pathol 2006;19:481–7.[CrossRef][Medline]
  38. Tubbs RR, Pettay JD, Swain E, et al. Automation of manual components and image quantification of direct dual label fluorescence in situ hybridization (FISH) for HER2 gene amplification: a feasibility study. Appl Immunohistochem Mol Morphol 2006;14:436–40.[CrossRef][Medline]
  39. Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 1994;220:391–8.[Medline]
  40. Bleiweiss IJ. Sentinel lymph nodes in breast cancer after 10 years: rethinking basic principles. Lancet Oncol 2006;7:686–92.[CrossRef][Medline]
  41. Hughes SJ, Xi L, Raja S, et al. A rapid, fully automated, molecular-based assay accurately analyzes sentinel lymph nodes for the presence of metastatic breast cancer. Ann Surg 2006;243:389–98.[CrossRef][Medline]
  42. Singletary SE, Allred C, Ashley P, et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 2002;20:3628–36.[Abstract/Free Full Text]
  43. Treseler P. Pathologic examination of the sentinel lymph node: what is the best method? Breast J 2006;12:S143–51.[CrossRef][Medline]
  44. Querzoli P, Pedriali M, Rinaldi R, et al. Axillary lymph node nanometastases are prognostic factors for disease-free survival and metastatic relapse in breast cancer patients. Clin Cancer Res 2006;12:6696–701.[Abstract/Free Full Text]
  45. Smeets A, Christiaens MR. Implications of the sentinel lymph node procedure for local and systemic adjuvant treatment. Curr Opin Oncol 2005;17:539–44.[CrossRef][Medline]
  46. Fournier K, Schiller A, Perry RR, Laronga C. Micrometastasis in the sentinel lymph node of breast cancer does not mandate completion axillary dissection. Ann Surg 2004;239:859–63.[CrossRef][Medline]
  47. Lynch MD, Cariati M, Purushotham AD. Breast cancer, stem cells, and prospects for therapy. Breast Cancer Res 2006;8:211.[CrossRef][Medline]
  48. Ponti D, Zaffaroni N, Capelli C, Daidone MG. Breast cancer stem cells: an overview. Eur J Cancer 2006;42:1219–24.[CrossRef][Medline]



This article has been cited by other articles:


Home page
 The OncologistHome page
J. S. Ross, E. A. Slodkowska, W. F. Symmans, L. Pusztai, P. M. Ravdin, and G. N. Hortobagyi
The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine
Oncologist, April 1, 2009; 14(4): 320 - 368.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
J. Permuth-Wey, D. Boulware, N. Valkov, S. Livingston, S. Nicosia, J.-H. Lee, R. Sutphen, J. Schildkraut, S. Narod, A. Parker, et al.
Sampling Strategies for Tissue Microarrays to Evaluate Biomarkers in Ovarian Cancer
Cancer Epidemiol. Biomarkers Prev., January 1, 2009; 18(1): 28 - 34.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
K. B. Horwitz
Commentary: The Year in Basic Science: Update of Estrogen Plus Progestin Therapy for Menopausal Hormone Replacement Implicating Stem Cells in the Increased Breast Cancer Risk
Mol. Endocrinol., December 1, 2008; 22(12): 2743 - 2750.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
K. B. Horwitz and C. A. Sartorius
Progestins in Hormone Replacement Therapies Reactivate Cancer Stem Cells in Women with Preexisting Breast Cancers: A Hypothesis
J. Clin. Endocrinol. Metab., September 1, 2008; 93(9): 3295 - 3298.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
R A Walker
Immunohistochemical markers as predictive tools for breast cancer
J. Clin. Pathol., June 1, 2008; 61(6): 689 - 696.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
J. S. Ross, C. Hatzis, W. F. Symmans, L. Pusztai, and G. N. Hortobagyi
Commercialized Multigene Predictors of Clinical Outcome for Breast Cancer
Oncologist, May 1, 2008; 13(5): 477 - 493.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ross, J. S.
Right arrow Articles by Hortobagyi, G. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ross, J. S.
Right arrow Articles by Hortobagyi, G. N.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online